Liver an Excellent Target for Cancer Gene Therapy

These findings signal a new way to treat cancers that have metastasized to the liver, such as metastatic cancers of the colon and breast.

The researchers, led by Tony Reid, M.D., Ph.D., of the Moores Cancer Center at University of California, San Diego (UCSD; USA), reported that in normal liver cells there is only one receptor--or the gateway the vector uses to enter the cell. This gateway is located at the base of normal liver cells, concealed from the blood vessels. The study, published in the February 14, 2007, issue of the journal Nature Cancer Gene Therapy, also demonstrated that in cancerous cells the receptor for adenovirus, called the coxsackie-adenoviral receptor (CAR), is expressed randomly over the surface of the cell and is exposed to the blood vessels.

"Since the receptor is distributed randomly on the surface of tumor cells, the doorway is open for the adenoviral vectors circulating in the blood stream to infect and kill these cells,” said Dr. Reid, who was at Stanford University (Stanford, CA, USA) when this study was conducted. "At the same time, normal liver cells are protected. These findings may signal a new way to treat any cancer that has spread to the liver.”

Dr. Reid explained, "We are taking advantage of a fundamental characteristic of cancer cells--structural disorganization. The disorganized structure of the cancer cells exposes the receptors so that Onyx-015, the adenoviral vectors used in this study, can readily enter tumor cells. This may be the first time a therapy has been directed against the disorganized nature of cancer cells.”

Dr. Reid and his colleagues undertook this study following the death of Jesse Gelsinger, a participant in a gene therapy clinical trial at University of Pennsylvania (Philadelphia, PA, USA) for ornithine transcarbanoylase (OTC) deficiency, a metabolic liver disorder. That case practically halted gene therapy research and initiated widespread safety concerns about gene therapy involving the liver.

"At that time, I was treating patients with colon cancer that had spread to the liver using a very similar adenoviral vector administered in exactly the same way--direct infusion into the main artery feeding the liver,” said Dr. Reid, who is now an associate professor of clinical medicine in the UCSD School of Medicine. "We saw virtually no problems with toxicity in 35 study participants who received a total of nearly 200 infusions across several study sites.”

Therefore, Dr. Reid and colleagues carefully re-analyzed the data from the 17 participants from the Stanford site to determine the impact of repeated adenoviral exposure on liver function, and confirmed that there were no significant problems. Whereas the study was not designed to demonstrate impact on disease, it showed that seven of the 17 patients had stable-to-improving disease prognosis at the completion of four viral infusions.

The researchers then demonstrated that normal liver cells could not be infected with an adenovirus, which led them to examine where the receptor was located. They found it hiding at the junction between liver cells and established that it was inaccessible from the blood flow in the liver. From there they showed that cancer cells had lost structural polarity, resulting in random distribution of CAR receptors on their surface, thereby allowing the virus to bind to and infect the tumor cells.

"In the process of proving that liver toxicity is not an issue in gene therapy, we have also shown that cancer cells metastatic to the liver are a perfect target for gene therapy because the cancer cells, but not the normal liver cells, are infected by the adenoviral vector,” said Dr. Reid. "We also found that other cancer cells, including those from the breast, pancreas, and prostate, are readily infected by adenoviral vectors indicating disorganized expression of the CAR receptor in these tumor cells. We believe these findings may have important implications across several types of cancer.”

The researchers stressed that while this study demonstrates that adenoviral vectors can be used to deliver targeted therapies and can be a useful tool for the treatment of cancer, additional clinical trials are needed.


Related Links:
University of California, San Diego